Amundi’s Regencell Bioscience RGC Stock Holding History

Amundi’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$287K	Buy	47,159 +38,564	+449%	+$926K	﹤0.01%	1856
2026 Q1	$219K	Buy	+8,595	New	+$243K	﹤0.01%	1848

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

FRM

Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return

Amundi's RGC Position: Q2 2026 in Review

Amundi increased its Regencell Bioscience (RGC) stake by 449% in Q2 2026, buying an estimated $926K and bringing the position to 47,159 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Amundi first reported a position in RGC in Q1 2026 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

Amundi held 47,159 shares of Regencell Bioscience worth $287K as of Q2 2026.
Amundi bought 38,564 Regencell Bioscience shares in Q2 2026, an estimated $926K.
Regencell Bioscience made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1856 holding.
Amundi first reported a position in Regencell Bioscience in Q1 2026 and has held it in 2 quarters since.
35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.